CCBs are recommended in the Eighth Joint National Committee (JNC8) guidelines to be used as a first-line treatment alone or in combination with other antihypertensives in all patients with hypertension regardless of age and race, except for patients with chronic kidney disease where angiotensin-converting enzyme inhibitors and angiotensin receptor blockers inhibitors are the recommended first-line treatment [47]. This evidence concerns the gene ACE and chronic kidney disease.